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Dear Sirs, 
Pancreatic cancer is an aggressive disease with a poor
prognosis but despite much investigation little is known
about genetic susceptibilities to this cancer [1-4]. 
There are several studies showing pancreatic
abnormalities in patients with Crohn’s disease,
a chronic inflammatory condition of the digestive tract. 
It has been suggested that pancreatitis could be an
extrahepatic manifestation of inflammatory bowel
disease, since its incidence in this disease is greater
than that in the general population and in many cases
no aetiological factor has been found [5]. It has been
recently identified in Japan that over 6% of Crohn’s
disease patients had morphological abnormalities of
the pancreas [6]. There is also a notion that Crohn’s-
associated pancreatitis could be a premalignant state
for cystadenocarcinoma of the pancreas [7]. 
Recently in patients with Crohn’s disease mutations
in CARD15/NOD2 have been found. NOD2 encodes
a protein involved in bacterial recognition by monocytes. 
The NOD2 gene is localized to chromosome 16
and is comprised of 12 exons that encode a protein of
1040 amino acids [8]. Several mutations have been
identified in the NOD2 gene, which appear with
a significantly higher frequency in patients with Crohn’s
disease. One such mutation (3020insC) is believed to
be clearly causative because it is the only common
variant which results in a prematurely truncated protein
predicted to reduce its functional efficiency. It has been
recognized recently that the presence of this particular
NOD2 mutation increases the risk of developing
colorectal cancer characterized by a later average age
of disease diagnosis [9]. Since the risk of cancers at
various sites has been characteristic among patients with
Crohn’s disease, it was considered justified to study the
relationship between the 3020insC mutation and other
cancer risks. Here, we report the analyses of the
3020insC mutation in the NOD2 gene in patients with
pancreatic cancer. 
Initially, we have examined the frequency of the
3020insC mutation in a series of 158 patients divided
into 3 groups: 
1. 127 consecutive pancreatic cancers; 
2. 4 familial cases – pancreatic cancer patients from
families with at least two pancreatic cancers on the
one side of the family; 
3. 27 healthy children of pancreatic cancer patients
from families with at least two pancreatic cancer
cases where DNA samples from affected individuals
were not available. 
Individuals from the last group were younger than
46 years. In the consecutive group peripheral blood
samples were available from 58 cases. DNA from the
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remaining patients was isolated from paraffin
embedded tissues. In all familial cases and the group
of healthy children DNA samples were obtained from
the peripheral blood lymphocytes. 
The control group consisted of 300 consecutive
newborns from the clinical hospitals of Szczecin. DNA
samples were obtained from umbilical cord blood. 
The method described by Ogura et al [8] was used
to identify the 3020insC mutation. The sequence of
the PCR products was confirmed by DNA sequencing. 
The frequency of the 3020insC mutation in the
control group was 7%. In the group of consecutive
cases six C-insertion mutations were identified (4.7%).
In the four independent familial pancreatic cancer
patients no mutation was found, but four changes
(14.8%; 4/27) were detected in the group of healthy
children of pancreatic cancer patients derived from
families with aggregations of these tumours (Fig. 1). 
Since our results indicated that there was an
increased frequency of the 3020insC mutation in familial
pancreatic cancer cases we decided to enlarge this
group. 30 additional histologically confirmed familial
pancreatic cancer patients of independent families from
the German National Case Collection for Familial
Pancreatic Cancer of the Deutsche Krebshilfe (FaPaCa)
were included in this study [10]. The frequency of the
mutant allele in this group did not confirm our initial
result since only two changes were found (6.7%; 2/30). 
However, even if Polish and German familial cases
are combined it is still an open question whether
3020insC is related to a predisposition to familial
pancreatic cancer. Further investigations on a larger
number of cases are needed. 
In summary we cannot conclude that NOD2 is not
involved in familial pancreatic cancer but it appears
not to be associated with sporadic cases of disease. 
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